Literature DB >> 21106943

The inotropic peptide βARKct improves βAR responsiveness in normal and failing cardiomyocytes through G(βγ)-mediated L-type calcium current disinhibition.

Mirko Völkers1, Christian Weidenhammer1, Oliver Friedrich1, Patrick Most1, Nicole Herzog1, Gang Qiu1, Kristin Spaich1, Frederic V Wegner1, Karsten Peppel1, Oliver J Müller1, Stefanie Schinkel1, Joseph E Rabinowitz1, Hans-Jorg Hippe1, Henriette Brinks1, Hugo A Katus1, Walter J Koch1, Andrea D Eckhart1.   

Abstract

RATIONALE: The G(βγ)-sequestering peptide β-adrenergic receptor kinase (βARK)ct derived from the G-protein-coupled receptor kinase (GRK)2 carboxyl terminus has emerged as a promising target for gene-based heart failure therapy. Enhanced downstream cAMP signaling has been proposed as the underlying mechanism for increased β-adrenergic receptor (βAR) responsiveness. However, molecular targets mediating improved cardiac contractile performance by βARKct and its impact on G(βγ)-mediated signaling have yet to be fully elucidated.
OBJECTIVE: We sought to identify G(βγ)-regulated targets and signaling mechanisms conveying βARKct-mediated enhanced βAR responsiveness in normal (NC) and failing (FC) adult rat ventricular cardiomyocytes. METHODS AND
RESULTS: Assessing viral-based βARKct gene delivery with electrophysiological techniques, analysis of contractile performance, subcellular Ca²(+) handling, and site-specific protein phosphorylation, we demonstrate that βARKct enhances the cardiac L-type Ca²(+) channel (LCC) current (I(Ca)) both in NCs and FCs on βAR stimulation. Mechanistically, βARKct augments I(Ca) by preventing enhanced inhibitory interaction between the α1-LCC subunit (Cav1.2α) and liberated G(βγ) subunits downstream of activated βARs. Despite improved βAR contractile responsiveness, βARKct neither increased nor restored cAMP-dependent protein kinase (PKA) and calmodulin-dependent kinase II signaling including unchanged protein kinase (PK)Cε, extracellular signal-regulated kinase (ERK)1/2, Akt, ERK5, and p38 activation both in NCs and FCs. Accordingly, although βARKct significantly increases I(Ca) and Ca²(+) transients, being susceptible to suppression by recombinant G(βγ) protein and use-dependent LCC blocker, βARKct-expressing cardiomyocytes exhibit equal basal and βAR-stimulated sarcoplasmic reticulum Ca²(+) load, spontaneous diastolic Ca²(+) leakage, and survival rates and were less susceptible to field-stimulated Ca²(+) waves compared with controls.
CONCLUSION: Our study identifies a G(βγ)-dependent signaling pathway attenuating cardiomyocyte I(Ca) on βAR as molecular target for the G(βγ)-sequestering peptide βARKct. Targeted interruption of this inhibitory signaling pathway by βARKct confers improved βAR contractile responsiveness through increased I(Ca) without enhancing regular or restoring abnormal cAMP-signaling. βARKct-mediated improvement of I(Ca) rendered cardiomyocytes neither susceptible to βAR-induced damage nor arrhythmogenic sarcoplasmic reticulum Ca²(+) leakage.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21106943      PMCID: PMC4013502          DOI: 10.1161/CIRCRESAHA.110.225201

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  52 in total

1.  Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer.

Authors:  S A Akhter; C A Skaer; A P Kypson; P H McDonald; K C Peppel; D D Glower; R J Lefkowitz; W J Koch
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

2.  Cardiac adenoviral S100A1 gene delivery rescues failing myocardium.

Authors:  Patrick Most; Sven T Pleger; Mirko Völkers; Beatrix Heidt; Melanie Boerries; Dieter Weichenhan; Eva Löffler; Paul M L Janssen; Andrea D Eckhart; Jeffrey Martini; Matthew L Williams; Hugo A Katus; Andrew Remppis; Walter J Koch
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

3.  Transgenic manipulation of beta-adrenergic receptor kinase modifies cardiac myocyte contraction to norepinephrine.

Authors:  D H Korzick; R P Xiao; B D Ziman; W J Koch; R J Lefkowitz; E G Lakatta
Journal:  Am J Physiol       Date:  1997-01

4.  A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension.

Authors:  Songling Liu; Richard T Premont; Christopher D Kontos; Shoukang Zhu; Don C Rockey
Journal:  Nat Med       Date:  2005-09-04       Impact factor: 53.440

5.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

Authors:  S Engelhardt; L Hein; F Wiesmann; M J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

6.  In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function.

Authors:  S A Akhter; A D Eckhart; H A Rockman; K Shotwell; R J Lefkowitz; W J Koch
Journal:  Circulation       Date:  1999-08-10       Impact factor: 29.690

7.  Level of beta-adrenergic receptor kinase 1 inhibition determines degree of cardiac dysfunction after chronic pressure overload-induced heart failure.

Authors:  Hideo Tachibana; Sathyamangla V Naga Prasad; Robert J Lefkowitz; Walter J Koch; Howard A Rockman
Journal:  Circulation       Date:  2005-01-24       Impact factor: 29.690

8.  Defective beta-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression.

Authors:  M C Cho; A Rapacciuolo; W J Koch; Y Kobayashi; L R Jones; H A Rockman
Journal:  J Biol Chem       Date:  1999-08-06       Impact factor: 5.157

9.  Phosphatidylinositol 3-kinase offsets cAMP-mediated positive inotropic effect via inhibiting Ca2+ influx in cardiomyocytes.

Authors:  Veronique Leblais; Su-Hyun Jo; Khalid Chakir; Victor Maltsev; Ming Zheng; Michael T Crow; Wang Wang; Edward G Lakatta; Rui-Ping Xiao
Journal:  Circ Res       Date:  2004-11-11       Impact factor: 17.367

10.  Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice.

Authors:  H A Rockman; D J Choi; S A Akhter; M Jaber; B Giros; R J Lefkowitz; M G Caron; W J Koch
Journal:  J Biol Chem       Date:  1998-07-17       Impact factor: 5.157

View more
  25 in total

Review 1.  Prospects for gene transfer for clinical heart failure.

Authors:  T Tang; M H Gao; H Kirk Hammond
Journal:  Gene Ther       Date:  2012-04-26       Impact factor: 5.250

2.  S100A1 DNA-based Inotropic Therapy Protects Against Proarrhythmogenic Ryanodine Receptor 2 Dysfunction.

Authors:  Julia Ritterhoff; Mirko Völkers; Andreas Seitz; Kristin Spaich; Erhe Gao; Karsten Peppel; Sven T Pleger; Wolfram H Zimmermann; Oliver Friedrich; Rainer H A Fink; Walter J Koch; Hugo A Katus; Patrick Most
Journal:  Mol Ther       Date:  2015-05-25       Impact factor: 11.454

Review 3.  G protein-coupled receptor kinases: more than just kinases and not only for GPCRs.

Authors:  Eugenia V Gurevich; John J G Tesmer; Arcady Mushegian; Vsevolod V Gurevich
Journal:  Pharmacol Ther       Date:  2011-08-26       Impact factor: 12.310

Review 4.  G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function.

Authors:  Douglas G Tilley
Journal:  Circ Res       Date:  2011-07-08       Impact factor: 17.367

5.  AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model.

Authors:  Philip W J Raake; Philipp Schlegel; Jan Ksienzyk; Julia Reinkober; Jens Barthelmes; Stefanie Schinkel; Sven Pleger; Walter Mier; Uwe Haberkorn; Walter J Koch; Hugo A Katus; Patrick Most; Oliver J Müller
Journal:  Eur Heart J       Date:  2012-01-19       Impact factor: 29.983

6.  Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.

Authors:  Mirko Völkers; Mathias H Konstandin; Shirin Doroudgar; Haruhiro Toko; Pearl Quijada; Shabana Din; Anya Joyo; Luis Ornelas; Kaitleen Samse; Donna J Thuerauf; Natalie Gude; Christopher C Glembotski; Mark A Sussman
Journal:  Circulation       Date:  2013-09-05       Impact factor: 29.690

Review 7.  The evolving impact of g protein-coupled receptor kinases in cardiac health and disease.

Authors:  Priscila Y Sato; J Kurt Chuprun; Mathew Schwartz; Walter J Koch
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

8.  Suppression of G-protein-coupled receptor kinase 3 expression is a feature of classical GBM that is required for maximal growth.

Authors:  B Mark Woerner; Jingqin Luo; Kristin R Brown; Erin Jackson; Sonika M Dahiya; Paul Mischel; Jeffrey L Benovic; David Piwnica-Worms; Joshua B Rubin
Journal:  Mol Cancer Res       Date:  2011-11-15       Impact factor: 5.852

Review 9.  Biased β2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery.

Authors:  Anthony Yiu-Ho Woo; Ying Song; Rui-Ping Xiao; Weizhong Zhu
Journal:  Br J Pharmacol       Date:  2014-12-17       Impact factor: 8.739

Review 10.  Heart failure-specific changes in protein kinase signalling.

Authors:  Kristina Lorenz; Konstantina Stathopoulou; Evelyn Schmid; Petra Eder; Friederike Cuello
Journal:  Pflugers Arch       Date:  2014-02-08       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.